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Abstract
Background: Pneumocystis jirovecii is an opportunistic
pathogen that causes pneumonia, particularly in immunode-
ficient hosts.
Materials and Methods: We retrospectively compared the
results obtained by two staining methods (toluidine blue
and calcofluor white) and two quantitative (q) real time
PCR assays for the detection of P. jirovecii in bronchoal-
veolar lavage (BAL) specimens. For the qPCR assays, we
used newly selected probes and primers targeting the Kex-1
gene, which codes for a serine endoprotease, and compared
the results to those from the published assay targeting the
b-tubulin gene.
Results: A total of 1,843 BAL specimens were analyzed
microscopically in parallel, and 74 (4.0%) were found to be
positive with both stains, 23 (1.2%) were positive only
with the toluidine blue stain, and six (0.3%) only with the
calcofluor stain (p = 0.003). Of these, a selection of 186
consecutive BAL fluid samples were tested by qPCR using
the respective different primer pairs. 21 of the 186 samples
(11.3%) were microscopically positive with both stains as
well as qPCR positive after 18–31 cycles (corresponding to
5.24 · 106 copies/ml to 640 copies/ml of native BAL)
using the Kex-1 primer pair and between 21–33 cycles
using the b-tubulin assay. A good correlation between
semi-quantitative microscopy and the number of PCR cycles
needed for a positive signal was noted. Of the remaining
165 samples, 153 (82%) were both microscopically and PCR
negative (PCR with the two sets of primers); the remaining
12 samples (7%) were Kex-1-based PCR positive (from
cycles 33 to 41, corresponding to 160 copies/ml of BAL or
less) but microscopically negative. Of these latter samples,
ten (6%) were also positive (from cycles 34 to 38) with
the primers targeting the b-tubulin gene. Taking micros-
copy as a reference, the sensitivity of qPCR targeting the
Kex-1 gene was 100%, and the specificity was 92.4%.
Conclusion: The sensitive qPCR analysis proved to be a
rapid and reliable method to detect P. jirovecii in BAL.
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Introduction
Pneumocystis jirovecii (synonym P. carinii sp. hominis) [1]
is a fungal opportunistic agent that causes pneumonia in
patients with impaired immunity [2]. Pulmonary pneu-
mocystosis remains one of the most frequent opportunis-
tic infections in AIDS patients who cannot benefit from
highly active antiretroviral therapy (HAART). In addi-
tion, other steadily increasing immunocompromised pa-
tients, such as those receiving immunosuppressive drugs
for organ transplantation, may also develop pneumocys-
tosis.
Since P. jirovecii cannot be cultured, the diagnosis is
conventionally based on a direct microscopic examination
of respiratory specimens; the sensitivities of such exam-
inations range from 48% to 92% in bronchoalveolar la-
vage (BAL) specimens and are lower in aspirates or
induced sputum [3, 4]. Nucleic acid amplification assays
have been developed and described with the aim of
improving the detection of P. jirovecii [5–8]. Many target
genes, such as dihydropteroate synthase (DHPS), dihy-
drofolate reductase (SHFR), internal transcribed spacer
regions of the rRNA (ITS), mitochondrial small subunit
rRNA (mtLSUrRNA), 5S rRNA, 18S rRNA, cdc2,
among others, have been described for the detection or
typing of this micro-organism [8–12]. However, there have
been frequent reports of some specimens yielding a po-
sitive conventional PCR signal when the microscopic
examination was negative. The advantage of a quantita-
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tive PCR (qPCR) is that the number of target gene copies
present in the specimens can be determined, which allows
a quantitative comparison with the results obtained by
microscopy. This information is especially useful for
specimens containing low numbers of P. jirovecii [13, 14].
The aims of the study reported here were (1) to ret-
rospectively quantify the differences between two staining
methods for the microscopic detection of P. jirovecii
based on a large number of routine results; (2) to establish
and evaluate a new quantitative TaqMan-based PCR for
the specific detection of P. jirovecii; (3) to determine the
number of PCR cycles corresponding to the detection
limit of the microscopic analysis.
Materials and Methods
In our institution BAL samples are routinely sent to dif-
ferent laboratories; with respect to the microscopic detection of
P. jirovecii, samples are most often sent to the Laboratoire des
Liquides Biologiques and to the Laboratoire Central de Bacte´-
riologie. We retrospectively compared the results communicated
by these two laboratories between January 1999 to June 2007 for
1,843 BAL specimens analyzed in parallel. The indication for
BAL specimen collection was determined by the pneumologists
based on respiratory symptoms, laboratory parameters, and
radiological observations. The vast majority of patients were
immunocompromised, some with severe respiratory failure.
The Laboratoire des Liquides Biologiques routinely uses a
toluidine blue stain [15] to detect P. jirovecii microscopically,
while the Laboratoire Central de Bacte´riologie uses a calcofluor
white fluorescent stain (Fungi-Fluor; Polysciences, Warrington,
PA) [4]. The Laboratoire des Liquides Biologiques also deter-
mines cell distribution and their concentration. To determine the
cell count found in the native fluid, the Laboratoire des Liquides
Biologiques concentrated BAL samples by centrifugation at 80 g
for 10 min. A volume of fluid (usually 100–200 ll) containing
120,000 cells was then introduced into each of two cyto-centri-
fuge funnels. Cyto-centrifugation at 150 g for 5 min produced
two slides that were air-dried and stained with toluidine blue [4].
In the Laboratoire Central de Bacte´riologie, 200 ll of undiluted
BAL samples were directly cyto-centrifuged (150 g). For statis-
tical comparison, the McNemar exact test was applied.
Of the 1,843 BAL samples compared retrospectively, we se-
lected 186 consecutive specimens collected from 143 patients (94
male, 49 female) for analysis by qPCR. All patients had signs and
symptoms and/or radiological abnormalities that included Pneu-
mocystis pneumonia as the differential diagnosis. According to the
130 clinical files available, 33 patients had organ transplantation
(of these 23 were lung transplantations), 19 were intubated in the
intensive care unit, 18 were known as HIV positive, 12 had cancer,
another 21 were otherwise immunocompromised, and the
remaining 27 suffered from other respiratory diseases. The BAL
procedures were performed following a standardized protocol.
Briefly, the flexible bronchoscope was placed in a wedged position
in a sub-segmental bronchus. Two to three 50-ml aliquots of iso-
tonic saline solution were instilled and immediately re-aspirated
with a typical return of 40%–60%. Samples were processed on the
same day as the microscopic examination.
For the PCR procedures, frozen (at –80 C) BAL samples
were thawed, and 500-ll aliquots were centrifuged for 10 min at
18,000 g. The pellet was re-suspended in the remaining 50 ll
BAL liquid after the supernatant had been discarded and was
then topped up to 200 ll with TE buffer (Tris 0.010 M + EDTA
0.001 M, pH 7.5). Thereafter, 30 ll lysis buffer (1.0 M Tris pH 9,
1.0 M KCl, 1% Triton X-100) containing proteinase K (3.3 mg/
ml, final concentration) was added and the mixture incubated for
1 h at 56 C, followed by 10 min at 95 C (enzyme inactivation).
200 ll of phenol–chloroform–isoamyl alcohol (25/24/1; v/v/v) was
added, mixed by vortexing (30 s), and centrifuged (2 min at
10,000 g); 150 ll of the aqueous DNA-containing phase was then
carefully transferred into a second tube, and 600 ll of ethanol
(100%) was added. The DNA was pelleted (5 min, 10,000 g) and
the supernatant discarded. The pellet was dried for a few minutes
at 56 C (heating block) and then re-suspended in 50 ll of water
(10–30 min, room temperature). For each sample, DNA was
extracted in triplicate.
Primers and probes of P. jirovecii were designed and se-
lected with the Primer Express Sequence Design software (Ap-
plied Biosystems, Foster City, CA). Candidate sequences were
checked to be specific for P. jirovecii by comparing them to
published sequences (http://www.ncbi.nlm.nih.gov/blast/Blas-
t.cgi). The Kex-1 gene coding for a serine endoprotease was
found to be unique for this organism. The probes were labeled
with 5-carboxyfluorescein at the 5¢-end and with 6-carboxy-
N,N,N¢,N¢-tetramethylrhodamine at the 3¢-end. The primers and
probe oligonucleotides sequences were: forward primer 5¢-CA-
ACCCTGTTCCAATGCCTAA-3¢, reverse primer 5¢-CAACAC
CGATTCCACAAACAGT-3¢, and probe 5¢-TGCTGGTG
AAGTAGCTGCCGTTCGA-3¢.
Real-time PCR assays were performed in the ABI PRISM
7700 Sequence Detection System (Applied Biosystems). Samples
were assayed in a 25-ll reaction mixture containing 5 ll of ex-
tracted DNA from the BAL. Primers and probes were used at a
final concentration of 50 nM. The PCR procedure was pro-
grammed for one cycle consisting of 2 min at 50 C (for the
digestion of previous amplification products) and 10 min at
95 C for inactivation of this enzyme and polymerase activation,
followed by 45 cycles of 15 s at 95 C and 60 C for 1 min.
Positive controls were included in each run: DNA extracted
from a BAL which was strongly positive based on the micro-
scopic analysis was serially diluted. The dilution giving a positive
signal after 30 cycles of amplification (threshold set at 0.02;
baseline taken from cycles 3 to 18) was retained for further
experiments. Aliquots were stored at 20 C. Spiked controls
were included for each BAL in order to detect PCR inhibitors.
All 186 BAL samples were tested with a second pair of
published primers targeting the b-tubulin gene sequence, which
has been shown to be a single copy gene in P. jirovecii [14]. These
primers were also found to be specific for P. jirovecii since
controls spiked with selected bacteria, fungi, viruses, as well as
human DNA have been found to be negative [14]. Primers tar-
geting the b-tubulin gene (forward: 5¢-GATCCGAGACATGG
TCGCTATT-3¢, reverse: 5¢-TTCAACCTCCTTCATGGAAAC
AG-3¢) and probe (5¢-Yakima Yellow-TGTTGCAGCGATT
TTCCGCGGTA-3¢-BlackAll) were used at the same concen-
trations and in the same conditions as for the Kex-1 gene. The Ct
values of Kex-1 versus b-tubulin primers and probe for the BAL
samples showed an excellent linear correlation (slope 0.9565,
correlation coefficient 0.97), and two almost parallel straight
lines (slopes 1.031 vs 1.058) were obtained over ten twofold
serial dilutions of positive control DNA, with the Kex-1 probe
being 2.2 cycles ahead of the b-tubulin probe under the condi-
tions used (results not shown). This slight difference in apparent
sensitivity between the Kex-1 and b-tubulin probe may be related
to the different fluorophores used.
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Results
Of the 1,843 BAL samples analyzed microscopically fol-
lowing staining with toluidine blue or calcofluor white,
103 (5.6%) were overall positive with one or the other
method, 74 were positive with both, 23 were positive only
with toluidine blue stain, and six were positive only with
calcofluor white (p = 0.003) (Table 1). If specimens that
were positive with both or either staining procedure are
considered to be a truly positive specimen (i.e., the gold
standard), the sensitivity of toluidine blue was 94% and of
calcofluor white 78%.
Of the 186 BAL specimens analyzed by microscopy
and the two PCR procedures, 21 (11.3%) were positive by
both staining methods and microscopy as well as with the
Kex-1-based PCR after 18–31 cycles (corresponding to
5.24 · 106 gene copies/ml to 640 copies/ml of BAL, cal-
culated as described below) and the b-tubulin-based PCR
after 21–33 cycles (Tables 2, 3; Figs. 1, 2). The qPCR as-
say obtained 33 (17.7%) positive specimens with the Kex-
1 probe and 31 (16.7%) positive specimens with the b-
tubulin probe (all 31 of the latter were also positive with
the Kex-1 probe; Tables 2, 3).
When the results from microscopy were considered as
the reference, the sensitivity of real time PCR using the
Kex-1 primers was 100%, the specificity 92.4%, the posi-
tive predictive value was 63.6% and negative predictive
value was 100%. The 12 Kex-1 qPCR-positive samples
were detected from cycles 33 (corresponding to 160 cop-
ies/ml of BAL) to 41 (Fig. 1). Therefore, a cut-off at 32
cycles (corresponding to 320 copies/ml of native BAL) for
the Kex-1 qPCR allowed a perfect agreement with
microscopy. For the b-tubulin qPCR, this correlation was
determined at a cut-off of 33 cycles (Fig. 2).
Detection limits of direct microscopy and the qPCR
were furthermore determined by diluting (log2) a strongly
positive BAL. The most diluted specimen that was
microscopically positive was positive by both qPCR at 33
cycles.
The medical charts for the 12 patients from whom the
BAL samples were microscopically negative but positive
by Kex-1-based qPCR from cycles ‡ 33 (corresponding to
£ 160 gene copies/ml of native BAL) were reviewed. All
of these patients were immunocompromised (transplan-
tation, HIV, or cancer). Five patients had bacterial or
other fungal pneumonia diagnosed by culture, four had
non-infectious acute respiratory distress syndrome, two
had cardiogenic pulmonary edema, and one patient had
Table 1
Comparison of toluidine blue and calcofluor white stains for the





Detection of P. jirovecii by calcofluor white
stain
Positive Negative Total
n % n % n %
Positive 74 4.0 23 1.2 97 5.3
Negative 6 0.3 1,740 94.4 1,746 94.7
Total 80 4.3 1,763 95.7 1,843 100.0
BAL, Bronchoalveolar lavage
Table 2
Comparison of microscopic and Kex-1 probe qPCR results for the




Detection of P. jirovecii by microscopy
Positive Negative Total
n % n % n %
Positive 21 11.3 12 6.5 33 17.7
Negative 0 153 82.3 153 82.3
Total 21 11.3 165 88.7 186 100.0
Table 3
Comparison of microscopy and b-tubulin probe qPCR results for




Detection of P. jirovecii by microscopy
Positive Negative Total
n % n % n %
Positive 21 11.3 10 5.4 31 16.7
Negative 0 155 83.3 155 83.3
Total 21 11.3 165 88.7 186 100.0
Figure 1. Correlation between semi-quantitative microscopy results
and the number of Kex-1 qPCR cycles required for positivity.
Individual results are represented by filled circles; averages and
corresponding standard deviations are denoted by horizontal bars.
(+ = few, ++ = many, +++ = abundant).
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sirolimus induced pneumopathy. Three patients died due
to their primary disease 24 h after the BAL collection,
another five had a clinical follow-up 2–16 months after the
bronchoscopy and from four of these five patients a con-
trol BAL was taken. All four control BAL specimens
were negative for P. jirovecii by microscopy and qPCR.
Discussion
Pneumocystis pneumonia in an immunocompromised
host is a severe and potentially fatal disease if adequate
treatment is not administered timely. We retrospectively
compared two different procedures and staining methods
routinely used to detect P. jirovecii microscopically and
found that the procedure with the toluidine blue stain
was significantly (p = 0.003) more sensitive (94%) than
that with the calcofluor white stain (78%). Similar results
have been previously reported, in particular in a study
comparing four staining methods where the sensitivity of
the calcofluor white stain was 74% [4]. The advantage of
the calcofluor white stain is that in addition to detecting
P. jirovecii cysts, it can also rapidly and reliably identify
fungal elements, since it binds non-specifically to b-
linked polysaccharides, such as chitin and cellulose [4].
The false negative results with the calcofluor white
method were mainly due to specimens containing low
numbers of P. jirovecii and for certain BAL specimens
that did not adhere to the slide. The appropriate BAL
fluid concentration based on the cell count we used for
the toluidine blue stain certainly contributed to the good
sensitivity achieved in our study with this stain. The
exact number of false positive results could not be
determined; however, we observed that such false posi-
tive results were rare because all 21 BAL specimens that
were microscopically positive were confirmed with two
qPCR methods of the selected consecutive 186 speci-
mens tested in parallel.
Many publications have reported that PCR has a
greater sensitivity and a better specificity than micro-
scopic analyses [6, 8, 13, 16, 17]. The advantage of a real
time PCR over classical PCR protocols is that the number
of target gene copies present in the specimens can be
determined. We successfully developed a quantitative real
time PCR allowing the rapid detection of P. jirovecii in
500 ll of BAL samples. By diluting a positive specimen
and determining the number of cysts visible by micros-
copy, we could estimate the dilution containing one cyst
per 50 ll. This dilution was positive at 36 PCR cycles.
From 33 cycles and more, microscopy was always nega-
tive, indicating that most specimens with very low cyst
numbers remain negative by microscopic analysis. In our
retrospective study we could not determine the clinical
significance of specimens microscopically negative but
qPCR positive between cycles 33 and 36 (corresponding
to 160 copies/ml to 20 copies/ml of BAL).
In order to determine the specificity of this Kex-1
probe, we compared the results to those obtained with the
published and well-evaluated b-tubulin probe [14]. These
results were identical with the exception of two samples,
which were only Kex-1 probe positive.
The possibility for detecting carriers by PCR analysis
is of considerable interest. Studies using nested PCR for
the detection of P. jirovecii in non-invasive samples ob-
tained from immunocompetent adults reported that 20%
were asymptomatic carriers [18] compared to 21.5%
among cystic fibrosis patients [19] and 19%–40% in a
population with primary pulmonary disorders [20, 21]. In
a further study, the authors suggested a cut-off of ‡ 10
gene copies/ll (corresponding to ‡ 50 gene-copies per
tube), as determined by serial dilutions of the cloned gene,
to discriminate infection from colonization [6]. In our
study, such BAL samples containing ‡ 10,000 copies/ml
were also microscopically positive, with the detection limit
determined at 320 gene copies/ml.
The number of Kex-1 PCR cycles needed for a posi-
tive signal correlated well with semi-quantitative micros-
copy results (Fig. 1). Only for semi-quantitative results of
++ and +++ was the difference marginal. We consider
qPCR to be more objective than semi-quantitative
microscopy, which relies essentially on experienced and
skilled personnel. In our experience, semi-quantitative
positive microscopy results do not correlate with the
severity of the disease; hosts factors certainly play a more
important role.
Figure 2. Correlation between semi-quantitative microscopy results
and number of b-tubulin probe quantitative (q) PCR cycles required
to positivity. Individual results are represented by ﬁlled circles;
averages and corresponding standard deviations by denoted by
horizontal bars.
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We obtained promising results in our ongoing study
using the same qPCR assay on non-invasive samples, such
as sputum and oro-pharyngeal swabs.
The sensitive real time PCR methods provided addi-
tional information to microscopic results. Their systematic
and prospective use will allow clinicians to determine the
clinical significance of positive qPCR results that are
negative based on microscopic analyses.
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